-
2
-
-
0041382438
-
Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications
-
DOI 10.1016/S0090-4295(03)00480-1
-
M.P. O'Leary Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications Urology. 62 Suppl 1 2003 15 23 (Pubitemid 41113200)
-
(2003)
Urology
, vol.62
, Issue.3 SUPPL. 1
, pp. 15-23
-
-
O'Leary, M.P.1
-
3
-
-
70449536472
-
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study
-
C.G. Roehrborn, P. Siami, J. Barkin, R. Damião, K. Major-Walker, and I. Nandi The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol. 57 2010 123 131
-
(2010)
Eur Urol.
, vol.57
, pp. 123-131
-
-
Roehrborn, C.G.1
Siami, P.2
Barkin, J.3
Damião, R.4
Major-Walker, K.5
Nandi, I.6
-
4
-
-
2442597011
-
Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias
-
DOI 10.1157/13060174
-
F.J. Antoñanzas Villar, C. Rubio-Terres, J.A. Sacristán, J.L. Pinto, L. Prieto, and J. Rovira Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias Med Clin. 122 2004 505 510 (Pubitemid 38649577)
-
(2004)
Medicina Clinica
, vol.122
, Issue.13
, pp. 505-510
-
-
Prieto, L.1
Sacristan, J.A.2
Antonanzas, F.3
Rubio-Terres, C.4
Pinto, J.L.5
Rovira, J.6
Antonanzas, F.7
Badia, X.8
Cobo, E.9
Garcia Alonso, F.10
Del Llano, J.11
Ortun, V.12
Pinto, J.L.13
Prieto, L.14
Rovira, J.15
Rubio, C.16
Sacristan, J.A.17
-
5
-
-
77950296007
-
Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias
-
J. López Bastida, J. Oliva, F. Antoñanzas, A. García-Altés, R. Gisbert, and J. Mar Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias Gac Sanit. 24 2010 154 170
-
(2010)
Gac Sanit.
, vol.24
, pp. 154-170
-
-
López Bastida, J.1
Oliva, J.2
Antoñanzas, F.3
García- Altés, A.4
Gisbert, R.5
Mar, J.6
-
6
-
-
77954865889
-
Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica
-
J. Mar, F. Antoñanzas, R. Pradas, and A. Arrospide Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica Gac Sanit. 24 2010 209 214
-
(2010)
Gac Sanit.
, vol.24
, pp. 209-214
-
-
Mar, J.1
Antoñanzas, F.2
Pradas, R.3
Arrospide, A.4
-
7
-
-
59749086003
-
Modelos de Markov: una herramienta útil para el análisis farmacoeconómico
-
C. Rubio-Terres, and A. Echevarría Modelos de Markov: una herramienta útil para el análisis farmacoeconómico Pharmacoec Sp Res Art. 3 2006 71 78
-
(2006)
Pharmacoec Sp Res Art.
, vol.3
, pp. 71-78
-
-
Rubio-Terres, C.1
Echevarría, A.2
-
8
-
-
79952313056
-
Distribución de Severidad Clínica y Prevalencia de Criterios de Progresión en Consulta de Urología en Pacientes con Hiperplasia Benigna de Próstata en España
-
12-15 Junio: Abstract C-41.
-
Miñana B, Layola M, Prieto M. Distribución de Severidad Clínica y Prevalencia de Criterios de Progresión en Consulta de Urología en Pacientes con Hiperplasia Benigna de Próstata en España. LXXIV Congreso Nacional de Urología. 12-15 Junio 2009: Abstract C-41.
-
(2009)
LXXIV Congreso Nacional de Urología
-
-
Miñana, B.1
Layola, M.2
Prieto, M.3
-
9
-
-
79952317922
-
-
Disponible en
-
Datos de mortalidad de varones mayores de 60 años (2001). Disponible en: http://www.who.int/whosis/database/life-tables/life-table- process.cfm?path=whosis,life-tables&language=english
-
(2001)
Datos de Mortalidad de Varones Mayores de 60 Años
-
-
-
10
-
-
0347882750
-
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
-
DOI 10.1056/NEJMoa030656
-
J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, and J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia NEJM. 349 2003 2387 2398 (Pubitemid 37542987)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.25
, pp. 2387-2398
-
-
McConnell, J.D.1
Roehrborn, C.G.2
Bautista, O.M.3
Andriole Jr., G.L.4
Dixon, C.M.5
Kusek, J.W.6
Lepor, H.7
McVary, K.T.8
Nyberg Jr., L.M.9
Clarke, H.S.10
Crawford, E.D.11
Diokno, A.12
Foley, J.P.13
Foster, H.E.14
Jacobs, S.C.15
Kaplan, S.A.16
Kreder, K.J.17
Lieber, M.M.18
Lucia, M.S.19
Miller, G.J.20
Menon, M.21
Milam, D.F.22
Ramsdell, J.W.23
Schenkman, N.S.24
Slawin, K.M.25
Smith, J.A.26
more..
-
11
-
-
77952309911
-
Criterios de derivación en hiperplasia benigna de próstata para atención primaria
-
J. Castiñeiras Fernández, J.M. Cozar Olmo, A. Fernández-Pro, J.A. Martín, F.J. Brenes Bermúdez, and E. Naval Pulido Criterios de derivación en hiperplasia benigna de próstata para atención primaria Actas Urol Esp. 34 2010 24 34
-
(2010)
Actas Urol Esp.
, vol.34
, pp. 24-34
-
-
Castiñeiras Fernández, J.1
Cozar Olmo, J.M.2
Fernández-Pro, A.3
Martín, J.A.4
Brenes Bermúdez, F.J.5
Naval Pulido, E.6
-
12
-
-
79952314602
-
Base de datos del Medicamento del Consejo General de Colegios Oficiales de Farmacéuticos
-
Disponible en
-
Base de datos del Medicamento del Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas. 2010. Disponible en: https://botplusweb.portalfarma.com/
-
(2010)
Catálogo de Especialidades Farmacéuticas
-
-
-
13
-
-
79952311558
-
Base de datos IMS Health Dataview
-
TAM. Agosto
-
Base de datos IMS Health Dataview. Datos de ventas y prescripción en España. TAM. Agosto 2010.
-
(2010)
Datos de Ventas y Prescripción en España
-
-
-
14
-
-
0017347943
-
Foundations of cost effectiveness analysis for health and medical practices
-
M.C. Weinstein, and W.B. Stason Foundations of cost-effective analysis for health and medical practices N Engl J Med. 296 1977 716 721 (Pubitemid 8066534)
-
(1977)
New England Journal of Medicine
, vol.296
, Issue.13
, pp. 716-721
-
-
Weinstein, M.C.1
Stason, W.B.2
-
15
-
-
0024354921
-
Methodology for measuring health-state preferences - Ll: Scaling methods
-
D.G. Froberg, and R.L. Kane Methodology for measuring health-state preferences - ll: scaling methods J Clin Epidemiol. 42 1998 459 471
-
(1998)
J Clin Epidemiol.
, vol.42
, pp. 459-471
-
-
Froberg, D.G.1
Kane, R.L.2
-
16
-
-
0026864403
-
Comparison of the cost-effectiveness of various therapies for common prostatic disorders
-
E.A. Amin, and M. Amin Comparison of the cost-effectiveness of various therapies for common prostatic disorders Pharmacoeconomics. 1 1992 357 369
-
(1992)
Pharmacoeconomics.
, vol.1
, pp. 357-369
-
-
Amin, E.A.1
Amin, M.2
-
17
-
-
0029971556
-
An economic evaluation of finasteride for treatment of benign prostatic hyperplasia
-
J.F. Baladi, D. Menon, and N. Otten An economic evaluation of finasteride for treatment of benign prostatic hyperplasia Pharmacoeconomics. 9 1996 443 454 (Pubitemid 26141901)
-
(1996)
PharmacoEconomics
, vol.9
, Issue.5
, pp. 443-454
-
-
Baladi, J.-F.1
Menon, D.2
Otten, N.3
-
18
-
-
0032324250
-
5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A department of veterans affairs cooperative study
-
R.C. Flanigan, D.J. Reda, J.H. Wasson, R.J. Anderson, M. Abdellatif, and R.C. Bruskewitz 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A department of veterans affairs cooperative study J Urol. 160 1998 12 16
-
(1998)
J Urol.
, vol.160
, pp. 12-16
-
-
Flanigan, R.C.1
Reda, D.J.2
Wasson, J.H.3
Anderson, R.J.4
Abdellatif, M.5
Bruskewitz, R.C.6
-
19
-
-
0027567741
-
Transurethral prostatectomay versus transurethral dilatiation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis
-
R.S. Bissonni, F.H. Lawler, and D.R. Holtgrave Transurethral prostatectomay versus transurethral dilatiation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis Famil Prac Res J. 13 1993 25 36
-
(1993)
Famil Prac Res J.
, vol.13
, pp. 25-36
-
-
Bissonni, R.S.1
Lawler, F.H.2
Holtgrave, D.R.3
-
20
-
-
0345828577
-
¿Qué es una tecnología sanitaria eficiente en España?
-
J.A. Sacristán, J. Oliva, J. del Llano, L. Prieto, and J.L. Pinto ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 16 2002 334 343
-
(2002)
Gac Sanit.
, vol.16
, pp. 334-343
-
-
Sacristán, J.A.1
Oliva, J.2
Del Llano, J.3
Prieto, L.4
Pinto, J.L.5
-
21
-
-
0029921839
-
An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden
-
C. Ahlstrand, P. Carlsson, and B. Jonsson An estimate of the life-time costs of surgical treatment of patients with benign prostatic hyperplasia In Sweeden Scan J Urol Nephro. 30 1996 37 43 (Pubitemid 26108070)
-
(1996)
Scandinavian Journal of Urology and Nephrology
, vol.30
, Issue.1
, pp. 37-43
-
-
Ahlstrand, C.1
Carlsson, P.2
Jonsson, B.3
-
22
-
-
0029552647
-
Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
-
DOI 10.1016/S0090-4295(99)80258-1
-
F.C. Lowe, R.C. McDaniel, J.J. Chmiel, and A.L. Hillman Economic modeling to assess the costs of treatment with finsateride, terazosin, transurectal resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Urology. 46 1995 477 483 (Pubitemid 26101337)
-
(1995)
Urology
, vol.46
, Issue.4
, pp. 477-483
-
-
Lowe, F.C.1
Mcdaniel, R.L.2
Chmiel, J.J.3
Hillman, A.L.4
-
23
-
-
0031886073
-
An introduction to Markov modelling for economic evaluation
-
DOI 10.2165/00019053-199813040-00003
-
A. Briggs, and M. Sculpher An introduction to Markov modeling for economic evaluation Pharmacoeconomics. 13 1998 397 409 (Pubitemid 28140699)
-
(1998)
PharmacoEconomics
, vol.13
, Issue.4
, pp. 397-409
-
-
Briggs, A.1
Sculpher, M.2
-
25
-
-
0027193264
-
Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem
-
A. Gafni, and S. Birch Guidelines for the adoption of new technologies: a prescription for uncontroleed growth in expenditures and how to avoid the problem CAMJ. 148 1993 913 917 (Pubitemid 23125540)
-
(1993)
Canadian Medical Association Journal
, vol.148
, Issue.6
, pp. 913-917
-
-
Gafni, A.1
Birch, S.2
-
26
-
-
51149098773
-
The NICE Cost-Effectiveness Threshold. What it is and what it means
-
C. McCabe, K. Claxton, and A.J. Culyer The NICE Cost-Effectiveness Threshold. What it is and what it means Pharmacoeconomics. 26 2008 733 744
-
(2008)
Pharmacoeconomics.
, vol.26
, pp. 733-744
-
-
McCabe, C.1
Claxton, K.2
Culyer, A.J.3
|